Why Shake Shack, Tesaro, and Square Slumped Today

Friday was a good day on Wall Street, especially for the large companies that make up the broadest major benchmarks. Market participants didn't let a slightly weak July employment report rain on their parade, instead insisting that the long-term course of the U.S. economy still looks overwhelmingly positive. Nevertheless, that general sentiment wasn't enough to prevent some stocks from posting considerable losses. Shake Shack (NYSE: SHAK) , Tesaro (NASDAQ: TSRO) , and Square (NYSE: SQ) were among the worst performers on the day. Here's why they did so poorly.

Shake Shack gets shaken

Shares of Shake Shack finished down 12% after the burger chain reported its second-quarter financial results. At first glance, the company's performance looked good, with a 27% boost to its top line helping to push adjusted earnings higher by more than half from year-ago levels. However, Shake Shack warned that future performance might not be quite as good, with guidance for the remainder of the year implying a growth slowdown that left some investors nervous about the stock's valuation. For shareholders who've grown used to Shake Shack not only exceeding expectations but also boosting its forward-looking projections, today's news just wasn't enough -- although it's essential to note that the shares are still up by nearly 80% over the past year even after today's drop.

Shake Shack location with a group of about 25 people posed in front of it on the street.

Image source: Shake Shack.

Tesaro looks a little sick

Tesaro stock plunged 24% after the biotech company's second-quarter report left investors disappointed . Even a near-doubling of revenue compared to the year-ago quarter wasn't enough to satisfy growth-hungry investors, who wanted to see better performance from ovarian cancer treatment Zejula. Shareholders didn't like how sales of anti-nausea treatment Varubi have fallen due to concerns about side effects, and now that Tesaro has decided to sell rights to Varubi to a third party, some worry that the biotech's prospects aren't as strong as they'd initially hoped. To recover, Tesaro will need to make good on its efforts to expand use of Zejula to more indications in order to broaden its target audience.

Square gives back its gains

Finally, shares of Square dropped 6%. The electronic payments specialist had jumped almost 9% on Thursday following the release of its second-quarter results, which included a nearly 50% jump in net revenue and 30% gains in transaction-based sales and gross payment volume. However, with the stock having nearly doubled just in 2018 alone, some shareholders appear to have had second thoughts about whether even Square's impressive growth rates are enough to justify current valuations. Square has plenty of promise in the long run, but investors should be prepared for volatility in both directions along the way.

Offer from The Motley Fool: The 10 best stocks to buy now

Motley Fool co-founders Tom and David Gardner have spent more than a decade beating the market. In fact, the newsletter they run, Motley Fool Stock Advisor , has tripled the S&P 500!*

Tom and David just revealed their ten top stock picks for investors to buy right now.

Click here to get access to the full list!

* Stock Advisor returns as of June 4, 2018.

Dan Caplinger has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Square. The Motley Fool has the following options: short September 2018 $80 calls on Square and long September 2018 $55 puts on Square. The Motley Fool has a disclosure policy .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

More Related Articles

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.